Transcenta Holding Limited 創勝集團醫藥有限公司 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 有關就解決截至2024年12月31日止年度的 年度報告內無法表示意見所採取措施及行動的最新進展 創勝集團醫藥有限公司（「本公司」，連同其附屬公司統稱為「本集團」）董事會 （「董事會」）謹此向股東及潛在投資者提供有關就解決其截至2024年12月31日止年 度的年度報告（「年報」）內所載的無法表示意見（「無法表示意見」）所採取措施及 行動的執行進度的最新進展。本公告所用但並無另行界定的詞彙應與年報中所賦 予該等詞彙的涵義相同。 自於2025年4月22日刊發年報、於2025年7月11日刊發最新進展公告、於2025年8 月27日刊發中期業績公告及於2025年10月22日刊發後續更新公告以來，本集團就 最初於年報內所載的九項關鍵措施持續取得切實進展，該等措施旨在增強其財務 狀況、提升流動性並解決無法表示意見。有關執行進度、狀況及預期成果的 ...

Core Insights - The company announced promising clinical results for osemitamab in combination with nivolumab and CAPOX as a first-line treatment for gastric or gastroesophageal junction adenocarcinoma, presented at the ESMO Asia Congress 2025 [1][2] Group 1: Clinical Trial Results - The updated efficacy analysis from the TranStar102 trial showed a median progression-free survival (mPFS) of 16.6 months and an objective response rate (ORR) of 68% among 26 patients with CLDN18.2 expression ≥40% and PD-L1 CPS known [1] - The median duration of response (mDoR) was reported at 18 months, indicating significant clinical benefits from the treatment [1] - Higher CLDN18.2 expression patients demonstrated better PFS regardless of PD-L1 expression levels, suggesting consistent potential therapeutic benefits [1] Group 2: Safety and Clinical Benefit - The safety profile of osemitamab was consistent with previously reported data from the ASCO 2025 conference, indicating good safety and tolerability [2] - The principal investigator highlighted the consistent clinical benefits across different PD-L1 subgroups, suggesting the treatment could provide significant improvements for advanced gastric or gastroesophageal junction adenocarcinoma patients [2] - The global clinical development executive vice president of the company expressed optimism about the strong clinical benefit signals and the potential of osemitamab to offer substantial benefits to patients in need of more effective treatment options [2]

Core Insights - The study results presented at the ESMO Asia Congress 2025 indicate that the combination therapy of osemitamab with nivolumab and CAPOX shows promising clinical benefits for patients with advanced gastric or gastroesophageal junction adenocarcinoma [1][2] Group 1: Clinical Efficacy - The updated efficacy analysis from the TranStar102 trial shows a median progression-free survival (mPFS) of 16.6 months and an objective response rate (ORR) of 68% among 26 patients with CLDN18.2 expression ≥40% and known PD-L1 CPS [1] - The median duration of response (mDoR) is reported to be 18 months, indicating sustained efficacy of the treatment [1] - Higher CLDN18.2 expression correlates with better PFS outcomes regardless of PD-L1 expression levels, suggesting consistent therapeutic benefits across different patient subgroups [1] Group 2: Safety and Tolerability - The safety profile of the combination therapy remains consistent with previously reported data, indicating good tolerability and safety [1][2] - The treatment is expected to provide significant clinical benefits to patients who urgently need more effective treatment options for advanced gastric or gastroesophageal junction adenocarcinoma [2]

Core Insights - The company announced positive results from the TranStar102 clinical trial, which evaluated osemitamab in combination with nivolumab and CAPOX for the treatment of gastric or gastroesophageal junction adenocarcinoma [1][2] - The updated efficacy analysis showed a median progression-free survival (mPFS) of 16.6 months and an objective response rate (ORR) of 68% among patients with high CLDN18.2 expression [1] - The results indicate that the treatment benefits of osemitamab are consistent across different PD-L1 expression subgroups, suggesting its potential effectiveness for a broader patient population [2] Efficacy Analysis - The study involved 26 patients with CLDN18.2 expression ≥40% and PD-L1 CPS known, with a median follow-up of 25.8 months [1] - The median duration of response (mDoR) was reported at 18 months, highlighting the durability of the treatment response [1] - The analysis confirmed that higher CLDN18.2 expression correlates with better PFS outcomes, regardless of PD-L1 expression levels [1] Safety Profile - The safety characteristics of the treatment were consistent with previously reported data from the ASCO 2025 conference [2] - The combination therapy demonstrated good safety and tolerability, reinforcing its potential as a first-line treatment option for advanced gastric or gastroesophageal junction adenocarcinoma [2] - The clinical benefits observed in the study are expected to provide significant improvements for patients in need of more effective treatment options [2]